Novo Nordisk names new CEO as it cuts growth outlook

Taking stock of the drug industry, from the lab to the medicine chest

July 29, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Novo Nordisk STAT+ | Novo Nordisk names new CEO as it cuts growth outlook The announcement came as Novo cut its 2025 outlook, citing slower growth of its obesity and diabetes drugs and competition from compounders. By Elaine Chen STAT+ | U.S. judge blocks first-in-the-nation law barring companies from owning PBMs and pharmacies in Arkansas A US district court judge agreed with the pharmacy benefit managers that the Arkansas law violated the Constitution. By Ed Silverman STAT+ | UnitedHealth CEO says some parts of business need 'fundamental reorientation' Stephen Hemsley, UnitedHealth's returning CEO, said parts of the firm need "fundamental reorientation," as it faces a range of challenges. By Bob Herman and Tara Bannow Adobe Opinion: How the FDA can score quick wins on transparency Upgrading how the FDA stores public data and documents about already-approved drugs would be a transparency win. By Frank David STAT+ | Fulcrum study results suggest a pill can treat sickle cell disease The pill increased levels of an alternate form of hemoglobin, but experts said more research is needed to demonstrate a benefit. By Jason Mast and Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser